Pfizer announced in February 2025 that it was taking Beqvez (fidanacogene elaparvovec), its gene therapy for hemophilia B, ...
Pfizer and BioMarin have pulled their hemophilia gene therapies, citing low demand. To prepare for his presentation at the ...
The US Food and Drug Administration (FDA) has released draft guidance on how sponsors can utilize next-generation sequencing ...
A groundbreaking gene therapy tested through a UCLA-led clinical trial has received approval from the U.S. Food and Drug ...
The FDA’s recently unveiled plausible mechanism framework may have been forged with i | The FDA’s newly launched plausible ...
Cell and gene therapies are moving towards correcting root causes of diseases. Let's take a look at future cell and gene therapy trends.
I am deeply humbled by the decades of support from people around the world. It is an honor to share this painful yet ...
From billionaire-backed biotech to promising animal studies, this early trial will test whether partial reprogramming can ...
Scientists have gained tremendous control over the genome with CRISPR editing systems, that use a guide RNA molecule to ...
Forbes contributors publish independent expert analyses and insights. A patient in a late-stage gene editing trial for a rare heart condition died from fatal liver complications after receiving an ...
Morning Overview on MSN
Compact CRISPR tool boosts in-body gene editing to 90% in lab tests
For the millions of people living with genetic diseases like muscular dystrophy and inherited liver disorders, one of the ...
1d
U.S. FDA Grants RMAT Designation to GS-100, Grace Science’s Gene Therapy to Treat NGLY1 Deficiency
Grace Science, LLC, a biotechnology company founded to develop novel therapies based on the function of NGLY1, announced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results